Vascular endothelium growth factor and insulin-like growth factors in prostaticcancer


Cite item

Full Text

Abstract

To study the levels of vascular endothelium growth factor
(VEGF), insulin-like growth factor of type I and II (IGF-I and IGF-II),
prostate-specific antigen (PSA) and their correlations in prostatic
cancer (PC) and benign prostatic hyperplasia (BPH), we examined
38 PC patients (mean age 66.6±5.5 years) and 80 BPH patients (mean
age 60.3+2.5 years). Serum concentrations of VEGF, IGF-I and
IGF-II were measured using kits made by R&D (USA), PSA by Boehringer
Mannheim (Germany). Sensitivity and specificity of the tests
were analysed by plotting the curves. The serum VEGF concentration
in PC patients was 518.9+60.7 pkg/ml, in BPH patients - 267.9+99.9
pkg/ml (p < 0.001). The IGF-I and IGF-II it was 178+19 and 136±9
ng/ml (p < 0.05), 400±31 and 351±23 ng/ml (p < 0.05), respectively.
The ratio of growth factor concentration to PSA concentration in the
blood serum in BPH patients was higher than in PC patients (p <0.01).
Sensitivity and specificity of PSA (4 ng/ml) made up 85.7 and
57%, VEGF (151.5 pg/ml) - 76.2 and 57.6%, IGF-I (157 ng/ml) -57.6
and 50%; IGF-II (392 ng/ml) - 57.5 and 50%, respectively. Sensitivity
and specificity VEGF/PSA was 85.7 and 70%; IGF-I/PSA -84.2
and 75%; IGF-II/PSA - 84.2 and 79.6%, respectively. Thus, the
ratio of concentrations of IGF-I, IGF-II and VEGF to PSA level in
blood serum has high sensitivity and specificity for PC detection.
Clinical implications of serum levels of VEGF, IGF-I and IGF-II
for prediction of PC course and detection is to be elicited

References

  1. Лопаткин Н. А. (ред.) Руководство по урологии. М.: Медицина; 1998.
  2. Аксель Е. М. Эпидемиология и статистика рака предстательной железы в России, странах Европы и США. В кн.:
  3. Кушлинский Н. Е., Соловьев Ю. Н., Трапезникова М. Ф. (ред.) Рак предстательной железы. М.; 2002: 11-20.
  4. Трапезников Н. И., Аксель Е. М. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 1998 г. М.; 2000.
  5. Kosary С. et al., eds. SEER Cancer statistics, 1973-1992. Tables and graphs. Bethesda; 1995.
  6. Oesterling J. E. Prostate specific antigen: critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. (Baltimore) 1991; 145: 907-923.
  7. Brawer M. K., Meyer G. E., Letran J. L. et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 1998; 52 (3): 372-378.
  8. Folkman J., Klagsburn M. Angiogenic factors. Science 1987; 235: 442-447.
  9. Weidner N., Carroll P. R., Flax J. et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1993; 143: 401-409.
  10. Griffiths K., Morton M. S., Denis L. Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer. Eur. Urol. 1999; 35: 443- 455.
  11. Bischoff J. Cell adhesion and angiogenesis. J. Clin, [nvest. 1997; 100 (11, suppl.): S37-S39.
  12. Ferrara N., Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. Experientia 1997; 79: 209-232.
  13. Takano S., Yoshii Y., Kondo S. et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 1996; 56 (9): 2185-2190.
  14. Brown L. F., Yeo К. Т., Berse B. et al. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J. Urol. (Baltimore) 1995; 154 (2, pt 1): 576- 579.
  15. Miyake H., Hara I., Yamanaka K. et al. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology 1999; 53 (2): 302-307.
  16. Zhang H. Т., Graft P., Scott P. A. et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J. Natl. Cancer Inst. 1995; 87 (3): 213-219.
  17. Duque J. L., Loughlin K. R., Adam R. M. et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54 (3): 523-527.
  18. Edgren M., Lennernas В., Larsson A., Nilsson S. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res. 1999; 19 (IB): 869-873.
  19. Jones A., Fujiyama C., Turner K. et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. Br. J. Urol. Int. 2000; 85 (3): 276-280.
  20. Iwamura M., SIuss P. M., Casamento J. B. et al. Insulin like growth factor 1: action and receptor characterization in human prostate cancer cell lines. Prostate 1993; 22: 243-252.
  21. Culig Z., Hobisch A., Cronauer M. V. et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor, keratinocyte growth factor and epidermal growth factor. Eur. Urol. 1995; 27 (2): 45-47.
  22. Holly J. Insulin-like growth factor 1 and new opportunities for cancer prevention. Lancet 1998; 351 (9113): 1373-1374.
  23. Mantzoros С. S., Tzonou A., Signorello L. B. et al. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br. J. Cancer 1997; 76: 1115-1118.
  24. Chan J. M., Stampfer M. J., Giovannuci E. et al. Plasma insulinlike growth factor 1 an prostate cancer risk: prospective study. Science 1998; 279: 563-566.
  25. Cohen P., Graves H., Peehl D. et al. Prostate-specific antigen is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab. 1992; 75 (4): 1046-1053.
  26. Djavan В., Bursa В., Seitz С. et al. Insulin like growth factor (1GF-I), IGF-I density and IGF-I/PSA ratio for prostate cancer detection. Urology 1999; 54 (4): 603-606.
  27. Catalona W. I, Smith D. S., Wolfert R. L. et al. Evaluation of percentage of free serum PSA to improve specificity of prostate cancer screening. J. A. M. A. 1995; 274: 1214-1220.
  28. Partin A. W., Carter H. B. The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. Urol. Clin. N. Am. 1996; 23: 531-540.
  29. Vashi A. R., Wojno K. J., Henricks W. et al. Determination of the "Reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49: 19-27.
  30. Stenman U.-H. Prostate-specific antigen: clinical use and staging an overview. Br. J. Urol. 1997; 79 (suppl. 1): 53-60.
  31. Brawer M. K., Partin A. The promise of new serum markers for prostate cancer. Contemp. Urol. 1999; 11 (3): 44-75.
  32. Katz L. E., Rosenfeld R. G., Cohen P. Clinical significance of IGFBPs. Endocrinologist 1995; 5: 41-48

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies